Maine Medical Center
- Type
- Teaching hospital
- Where
- Portland, ME
- Medicare CCN
- 200009
- Received
- $1,338,338 in 256 records, 2024 ($91,913 general, $1,246,424 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: Maine Medical Center Fuzzy (name and state)
- Lobbying client: MAINE MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: Maine Medical Center Fuzzy (name and state)
- Trademark owner: Maine Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 16 | $91,913 |
| 2024 | Research payment | 240 | $1,246,424 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 240 | $1,246,424 |
| Grant | 1 | $46,405 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $18,400 |
| Debt forgiveness | 5 | $11,148 |
| Long term medical supply or device loan | 4 | $9,209 |
| Charitable Contribution | 1 | $4,000 |
| Space rental or facility fees (teaching hospital only) | 2 | $1,750 |
| Royalty or License | 1 | $1,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | OCCLUTECH US LLC | $46,405 | Grant (3 payments) | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | HEARTFLOW, INC. | $18,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FFRct Device, Coronary | 2024 | |
| 2024-12-31 | Stryker Corporation | $7,768 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,993 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $34 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-20 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-20 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-12-18 | PFIZER INC. | $20,111 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-12-18 | Travere Therapeutics, Inc. | $2,000 | Research payment | Cash or cash equivalent | OT-58 AS AN ENZYME THERAPY FOR PATIENTS WITH HOMOCYSTINURIA CAUSED BY CYSTATHIONINE BETA-SYNTHASE DEFICIENCY | 2024 | |
| 2024-12-18 | SANOFI US SERVICES INC. | $250 | Research payment | Cash or cash equivalent | LUMIZYME Biological, Genetic Disease | Pompe Disease Registry | 2024 |
| 2024-12-11 | Travere Therapeutics, Inc. | $1,814 | Research payment | Cash or cash equivalent | OT-58 AS AN ENZYME THERAPY FOR PATIENTS WITH HOMOCYSTINURIA CAUSED BY CYSTATHIONINE BETA-SYNTHASE DEFICIENCY | 2024 | |
| 2024-12-10 | Boston Scientific Corporation | $2,600 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | ASAP- TOO | 2024 |
| 2024-11-29 | Novocure GmbH | $1,000 | Research payment | Cash or cash equivalent | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2024 | |
| 2024-11-23 | PFIZER INC. | $16,835 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-11-20 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $390 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-11-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-11-20 | Linvatec Corporation | $41 | Long term medical supply or device loan | In-kind items and services | LINVATEC EXTREMITIES Device, ORTHOPEDIC SURGERY | 2024 | |
| 2024-11-15 | Indivior Inc. | $906 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-11-15 | Indivior Inc. | $279 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-11-14 | Aveo Pharmaceuticals, Inc. | $19,150 | Research payment | Cash or cash equivalent | TBD - WCT/AVEO | 2024 | |
| 2024-11-06 | Travere Therapeutics, Inc. | $10,250 | Research payment | Cash or cash equivalent | TVTX-TV058-302 | 2024 | |
| 2024-10-31 | Philips North America LLC | $6,050 | Research payment | Cash or cash equivalent | (9532) PD Other Device, Medical Device | ECS Study | 2024 |
| 2024-10-29 | PFIZER INC. | $260 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-10-24 | Silk Road Medical, Inc. | $650 | Research payment | Cash or cash equivalent | ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter Device, Cardiology/Vascular Diseases | Roadster 3 | 2024 |
| 2024-10-23 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-10-21 | Indivior Inc. | $279 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-10-21 | Indivior Inc. | $279 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-10-14 | Indivior Inc. | $414 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-10-08 | PFIZER INC. | $91 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-10-07 | Celgene Corporation | $13,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of RPC-1063 in Patients with Ulcerative Colitis | 2024 | |
| 2024-10-03 | pharmaand GmbH | $427 | Research payment | Cash or cash equivalent | Rubraca Drug, PARP inhibitor | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2024 |
| 2024-09-30 | Medical Device Business Services, Inc. | $3,832 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2024 |
| 2024-09-30 | Philips North America LLC | $3,300 | Research payment | Cash or cash equivalent | (9532) PD Other Device, Medical Device | ECS Study | 2024 |
| 2024-09-30 | PFIZER INC. | $2,450 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2024 |
| 2024-09-30 | Medical Device Business Services, Inc. | $758 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2024 |
| 2024-09-28 | PFIZER INC. | $2,193 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-09-27 | PFIZER INC. | $26,565 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-09-26 | ABBVIE INC. | $125 | Research payment | Cash or cash equivalent | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | 2024 | |
| 2024-09-25 | Indivior Inc. | $906 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-09-25 | Indivior Inc. | $279 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-09-25 | Indivior Inc. | $279 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-09-25 | Indivior Inc. | $279 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-09-25 | Indivior Inc. | $279 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-09-24 | pharmaand GmbH | $7,875 | Research payment | Cash or cash equivalent | Rubraca Drug, PARP inhibitor | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2024 |
| 2024-09-23 | Servier BioInnovation | $43,869 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-09-23 | Servier BioInnovation | $43,869 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-09-20 | ABBVIE INC. | $1,100 | Research payment | Cash or cash equivalent | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) | 2024 | |
| 2024-09-19 | Servier BioInnovation | $43,869 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-09-19 | Servier BioInnovation | $43,869 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-09-18 | Smith+Nephew, Inc. | $4,367 | Debt forgiveness | Cash or cash equivalent | Coblation Device, Sports Med Access | 2024 | |
| 2024-09-18 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-09-18 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-09-18 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-09-18 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-09-18 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-09-18 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-09-18 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-09-18 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-09-18 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-09-06 | Travere Therapeutics, Inc. | $278 | Research payment | Cash or cash equivalent | OT-58 AS AN ENZYME THERAPY FOR PATIENTS WITH HOMOCYSTINURIA CAUSED BY CYSTATHIONINE BETA-SYNTHASE DEFICIENCY | 2024 | |
| 2024-09-05 | ABBVIE INC. | $143 | Research payment | Cash or cash equivalent | A Trial of the Efficacy and Safety of?CVL-865?as Adjunctive Therapy in the Treatment of Focal Onset Seizures | 2024 | |
| 2024-09-04 | Genmab A/S | $6,747 | Research payment | Cash or cash equivalent | A Phase 2 Exploratory, Multicenter, Open-Label Trial to Determine the Safety and Preliminary Clinical Activity of GEN104 | 2024 | |
| 2024-09-04 | Indivior Inc. | $390 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-09-01 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2024 |
| 2024-09-01 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2024 |
| 2024-08-31 | Philips North America LLC | $2,750 | Research payment | Cash or cash equivalent | (9532) PD Other Device, Medical Device | ECS Study | 2024 |
| 2024-08-29 | Janssen Research & Development, LLC | $2,032 | Research payment | Cash or cash equivalent | A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study to Evaluate the Efficacy Safety and Toler | 2024 | |
| 2024-08-29 | ABBVIE INC. | $300 | Research payment | Cash or cash equivalent | An Open-label Extension Trial of?CVL-865?as Adjunctive Therapy in the Treatment of Focal Onset Seizures | 2024 | |
| 2024-08-27 | LivaNova USA, Inc. | $2,870 | Debt forgiveness | Cash or cash equivalent | Perfusion Tubing Device, Cardiology/Vascular Diseases | 2024 | |
| 2024-08-26 | Janssen Research & Development, LLC | $1,250 | Research payment | Cash or cash equivalent | A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study to Evaluate the Efficacy Safety and Toler | 2024 | |
| 2024-08-23 | Indivior Inc. | $906 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-08-23 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $279 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-08-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-23 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-08-22 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-08-15 | ABBVIE INC. | $3,000 | Research payment | Cash or cash equivalent | A Trial of the Efficacy and Safety of?CVL-865?as Adjunctive Therapy in the Treatment of Focal Onset Seizures | 2024 | |
| 2024-08-15 | ABBVIE INC. | $1,166 | Research payment | Cash or cash equivalent | A Trial of the Efficacy and Safety of?CVL-865?as Adjunctive Therapy in the Treatment of Focal Onset Seizures | 2024 | |
| 2024-08-14 | Servier BioInnovation | $1,632 | Research payment | Cash or cash equivalent | Tibsovo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-08-14 | Servier BioInnovation | $1,274 | Research payment | Cash or cash equivalent | Tibsovo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-08-12 | Servier BioInnovation | $43,869 | Research payment | In-kind items and services | Voranigo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-08-08 | Silk Road Medical, Inc. | $1,595 | Research payment | Cash or cash equivalent | ENROUTE Transcarotid Neuroprotection System Device, Cardiology/Vascular Diseases | Roadster 3 | 2024 |
| 2024-08-08 | Silk Road Medical, Inc. | $845 | Research payment | Cash or cash equivalent | ENROUTE Transcarotid Stent Device, Cardiology/Vascular Diseases | Roadster 3 | 2024 |
| 2024-08-07 | ZOLL Circulation Inc | $11,000 | Research payment | Cash or cash equivalent | TherOx DS2 Console Device, TherOx Therapy | AMIHOT3 | 2024 |
| 2024-08-02 | ABBVIE INC. | $3,215 | Research payment | Cash or cash equivalent | A Trial of the Efficacy and Safety of?CVL-865?as Adjunctive Therapy in the Treatment of Focal Onset Seizures | 2024 | |
| 2024-07-26 | National Marrow Donor Program | $5,500 | Research payment | Cash or cash equivalent | A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for N | 2024 | |
| 2024-07-22 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $492 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $279 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-07-22 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-22 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-07-18 | Silk Road Medical, Inc. | $2,860 | Research payment | Cash or cash equivalent | ENROUTE Transcarotid Neuroprotection System Device, Cardiology/Vascular Diseases | Roadster 3 | 2024 |
| 2024-07-10 | Smith+Nephew, Inc. | $1,883 | Debt forgiveness | Cash or cash equivalent | FOOTPRINT Device, Extremities & Limb Restoration | 2024 | |
| 2024-07-09 | PFIZER INC. | $2,580 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-07-08 | Abbott Laboratories | $4,000 | Charitable Contribution | Cash or cash equivalent | ALERE BINAXNOW INFLUENZA A & B CARD 2 Device, Rapid Diagnostics | 2024 | |
| 2024-07-05 | Boston Scientific Corporation | $12,100 | Research payment | Cash or cash equivalent | Lumenis Pulse 120H Device, Lumenis Pulse 120H_URO | Comparison of Lumenis Pulse 120H Moses 2.0 Holmium Laser Versus Olympus Soltive Thulium Fiber Laser for Mini-Percutaneou | 2024 |
| 2024-07-05 | Boston Scientific Corporation | $3,000 | Research payment | Cash or cash equivalent | Lumenis Pulse 120H Device, Lumenis Pulse 120H_URO | Comparison of Lumenis Pulse 120H Moses 2.0 Holmium Laser Versus Olympus Soltive Thulium Fiber Laser for Mini-Percutaneou | 2024 |
| 2024-07-03 | Servier BioInnovation | $2,011 | Research payment | Cash or cash equivalent | Tibsovo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-07-03 | ZOLL Circulation Inc | $2,000 | Research payment | Cash or cash equivalent | TherOx DS2 Console Device, TherOx Therapy | AMIHOT3 | 2024 |
| 2024-07-03 | Servier BioInnovation | $1,000 | Research payment | Cash or cash equivalent | Tibsovo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-07-03 | Servier BioInnovation | $500 | Research payment | Cash or cash equivalent | Tibsovo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-07-03 | Servier BioInnovation | $500 | Research payment | Cash or cash equivalent | Tibsovo Drug, Oncology | STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I | 2024 |
| 2024-06-30 | Philips North America LLC | $4,950 | Research payment | Cash or cash equivalent | (9532) PD Other Device, Medical Device | ECS Study | 2024 |
| 2024-06-30 | Philips North America LLC | $3,763 | Research payment | Cash or cash equivalent | (9532) PD Other Device, Medical Device | ECS Study | 2024 |
| 2024-06-27 | PFIZER INC. | $63,671 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-06-25 | PFIZER INC. | $23,673 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-06-25 | Indivior Inc. | $906 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-06-25 | Indivior Inc. | $906 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-06-25 | Indivior Inc. | $279 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-06-24 | Servier BioInnovation | $1,274 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurr | 2024 | |
| 2024-06-24 | Servier BioInnovation | $1,274 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurr | 2024 | |
| 2024-06-21 | BioMarin Pharmaceutical Inc. | $1,000 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-06-21 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-06-21 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-06-21 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-06-21 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-06-21 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-06-21 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-06-21 | Indivior Inc. | $207 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-06-12 | Indivior Inc. | $5,200 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-06-12 | Indivior Inc. | $325 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV STUDY TO EVALUATE THE SUBLOCADE TREATMENT EXIT STRATEGY | 2024 |
| 2024-06-11 | Boston Scientific Corporation | $336 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | ASAP- TOO | 2024 |
| 2024-06-07 | PFIZER INC. | $42,659 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-05-31 | Philips North America LLC | $5,500 | Research payment | Cash or cash equivalent | (9532) PD Other Device, Medical Device | ECS Study | 2024 |
| 2024-05-27 | Janssen Research & Development, LLC | $2,933 | Research payment | Cash or cash equivalent | A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study to Evaluate the Efficacy Safety and Toler | 2024 | |
| 2024-05-27 | Janssen Research & Development, LLC | $551 | Research payment | Cash or cash equivalent | A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study to Evaluate the Efficacy Safety and Toler | 2024 | |
| 2024-05-27 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Randomized Double Blind Placebo Controlled Parallel Group Multi Center Study to Evaluate the Efficacy Safety and Toler | 2024 | |
| 2024-05-24 | SANOFI US SERVICES INC. | $800 | Research payment | Cash or cash equivalent | FABRAZYME Biological, Genetic Disease | Fabry Disease Registry Protocol | 2024 |
| 2024-05-18 | PFIZER INC. | $29,784 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-05-17 | Indivior Inc. | $754 | Research payment | Cash or cash equivalent | SUBLOCADE Drug, OUD | A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISOR | 2024 |
| 2024-05-17 | SANOFI US SERVICES INC. | $350 | Research payment | Cash or cash equivalent | CEREZYME Biological, Genetic Disease | Gaucher Disease Registry Protocol | 2024 |
The latest 200 records of 256.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Portland, ME, county Cumberland County, ME, state Maine; placed by its city name.
| Measure | Place (city or town) Portland, ME | County Cumberland County, ME | State Maine |
|---|---|---|---|
| Population B01003 | 68,854 | 308,827 | 1,387,817 |
| Population, 2020 census P1 | 68,408 | 303,069 | 1,362,359 |
| Median age B01002 | 37.8 | 42.2 | 44.8 |
| Under 18 B01001 | 15.4% | 18.0% | 18.1% |
| 65 and over B01001 | 16.9% | 20.4% | 22.4% |
| Households B11001 | 32,965 | 132,168 | 597,159 |
| Foreign born B05002 | 11.8% | 6.7% | 4.1% |
| Median household income B19013 | $79,540 | $95,677 | $74,733 |
| Median family income B19113 | $118,777 | $124,273 | $96,912 |
| Per capita income B19301 | $52,781 | $55,739 | $43,742 |
| Poverty rate B17001 | 11.2% | 7.3% | 10.7% |
| Unemployment rate B23025 | 4.2% | 3.1% | 3.8% |
| Civilian labor force B23025 | 42,094 | 175,357 | 719,683 |
| Mean commute (minutes) B08013 | 19.4 | 23.2 | 24.6 |
| Bachelor's degree or higher B15003 | 59.7% | 53.0% | 36.2% |
| Housing units B25001 | 36,559 | 153,286 | 751,876 |
| Owner-occupied B25003 | 46.9% | 69.8% | 74.3% |
| Renters B25003 | 53.1% | 30.2% | 25.7% |
| Median home value B25077 | $489,600 | $451,200 | $296,600 |
| Median gross rent B25064 | $1,577 | $1,589 | $1,139 |
| White, not Hispanic B03002 | 77.5% | 85.6% | 89.9% |
| Black B03002 | 9.1% | 3.4% | 1.8% |
| Hispanic or Latino B03002 | 3.1% | 2.8% | 2.2% |
| Asian B03002 | 3.9% | 2.2% | 1.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Portland, ME.
Comments